Regenerative Medicine Market
Number of pages: 100 | Report Format: PDF | Published date: January 28, 2022
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023 to 2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 11.9 billion |
|
Revenue Forecast in 2031 |
US$ 85.52 billion |
|
CAGR |
24.5% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Type, Application, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global regenerative medicine market was valued at US$ 11.9 billion in 2022 and is expected to register a revenue CAGR of 24.5% to reach US$ 85.52 billion by 2031.
Regenerative Medicine Market Fundamentals
Regenerative medicine is an interdisciplinary field of medicine that focuses on developing innovative approaches to repair, replace, or regenerate damaged or diseased cells, tissues, or organs. Its goal is to restore normal function and improve the quality of life for individuals suffering from various medical conditions. Regenerative medicine incorporates principles from biology, chemistry, genetics, engineering, and other scientific disciplines to create advanced therapies that promote the body's natural healing process. It seeks to go beyond traditional treatments that merely manage symptoms or slow down disease progression by restoring the structure and function of damaged tissues or organs. Regenerative medicine has shown promise in treating many conditions, including cardiovascular diseases, neurodegenerative disorders, musculoskeletal injuries, diabetes, organ failure, and more. It offers the potential for more effective, long-lasting treatments that address the underlying causes of diseases rather than just managing symptoms.
[3029239]
Regenerative Medicine Market Dynamics
Chronic diseases, such as cardiovascular disorders, diabetes, neurodegenerative diseases, and orthopedic conditions, are significant healthcare burdens worldwide and are a primary driver for the growth of the global regenerative medicine market. Regenerative medicine holds the potential to provide innovative and more effective treatments for these conditions, driving the demand for regenerative therapies. According to the WHO’s factsheet of June 2021, cardiovascular disease is one of the leading causes of death, which caused around 17.9 million deaths in 2019. Stem cells have earned significant attention due to their ability to differentiate into various cell types and regenerate damaged tissues. Advancements in stem cell research, including the discovery of induced pluripotent stem cells (iPSCs) and improved techniques for isolating and manipulating stem cells, have expanded the potential applications of regenerative medicine.
Moreover, advances in biotechnology, biomaterials, tissue engineering, gene editing, and other related fields have facilitated the development of new regenerative medicine therapies. These technological innovations enable the production of functional tissues and organs, enhance the delivery of therapeutic agents, and improve the overall efficacy of regenerative treatments, are also boosting the overall growth of the global regenerative medicine market. Furthermore, the regenerative medicine sector has attracted significant private and public investments. Governments, research institutions, and pharmaceutical companies are investing in regenerative medicine research and development, fostering collaborations, and accelerating the translation of scientific discoveries into clinical applications, which is fueling the growth of the regenerative medicine market.
However, developing regenerative medicine therapies can be extremely costly. The research and development process often involves extensive preclinical and clinical studies, manufacturing challenges, and regulatory compliance, which require a significant financial investment. The high costs associated with development can hinder the progress and accessibility of regenerative medicine treatments. The manufacturing processes for regenerative medicine products, such as stem cell therapies or tissue-engineered constructs, can be technically challenging and resource-intensive. Maintaining consistent quality, scalability, and reproducibility in producing these therapies is crucial for commercialization. The complexity of manufacturing can increase costs, limit production capacity, and hinder the widespread availability of regenerative medicine treatments. Additionally, complex manufacturing processes, regulatory challenges, and high development costs are some of the restraints impeding overall regenerative medicine market growth.
Regenerative Medicine Market Ecosystem
The global regenerative medicine market is analyzed from three perspectives: type, application, and region.
Regenerative Medicine Market by Type
[4552343]
Based on the type, the global regenerative medicine market is segmented into cell therapy, tissue engineering, and gene therapies.
The cell therapy segment dominated the market with the principal revenue share in 2022. The cell therapy segment is a key component of the regenerative medicine market, focusing on using cells to treat and repair damaged or diseased tissues and organs. Cell therapy involves administering living cells from the patient's body (autologous) or from a donor (allogeneic) to promote tissue regeneration, enhance healing, or modulate the immune response. Cell therapy encompasses various cell types, including stem cell therapies, progenitor cell therapies, and cell-based immunotherapy. Stem cells, such as embryonic stem cells, adult stem cells, and induced pluripotent stem cells (iPSCs), can self-renew and differentiate into different cell types. Stem cell therapy involves the isolation and expansion of these cells in the laboratory, followed by their transplantation into the patient to replace damaged or dysfunctional cells and promote tissue regeneration. These aspects contribute to the growth of the cell therapy segment.
The gene therapies segment accounted for the second-largest revenue share. They are focusing on using genetic material to treat or modify genetic disorders, inherited diseases, and other conditions at the molecular level. Gene therapy involves the introduction of therapeutic genes or genetic material into a patient's cells to correct genetic mutations, restore normal gene function, or modulate gene expression. Gene therapies can provide long-lasting or permanent solutions for genetic diseases as they address the underlying genetic cause. However, there are challenges associated with gene therapy, including t delivery of therapeutic genes to target cells, potential immune responses, off-target effects, and long-term safety monitoring. These aspects contribute to the growth of the gene therapies segment.
Regenerative Medicine Market by Application
Based on the application, the global regenerative medicine market is segmented into oncology, musculoskeletal disorders, wound care, ocular disorders, cell transplantation, cardiovascular, and others.
The oncology segment dominated the market with the largest revenue share of 33%, owing to the rising prevalence of cancer globally. For instance, according to the WHO’s factsheet of February 2022, cancer accounted for nearly 10 million deaths in 2020, and prostate cancers, lung, breast, colon, and rectum were the most common types of cancer. Regenerative medicine in the oncology segment focuses on developing innovative cancer treatments. Regenerative medicine approaches within oncology aim to leverage cellular and molecular techniques to enhance the body's natural ability to fight cancer, target tumor cells, and restore tissue function. Several approaches are being explored in regenerative medicine for cancer treatment, including cellular immunotherapies, gene therapies, and tissue engineering for cancer reconstruction. These factors contribute to the growth of the oncology segment.
Musculoskeletal disorders accounted for the second-largest revenue share of the market, owing to the increasing prevalence of these disorders. For instance, according to the WHO’s article of July 2022, around 1.71 million individuals suffer from musculoskeletal disorders globally. Regenerative medicine in musculoskeletal disorders focuses on developing innovative therapies to treat and repair injuries or degenerative conditions affecting the musculoskeletal system. Musculoskeletal disorders encompass various conditions that affect the bones, joints, muscles, tendons, ligaments, and other connective tissues. Musculoskeletal disorders, such as osteoarthritis, ligament injuries, cartilage defects, and bone fractures, are prevalent and can significantly impact an individual's quality of life. Regenerative medicine approaches for musculoskeletal disorders aim to address the underlying causes of these conditions, promote tissue repair and regeneration, and provide long-lasting solutions beyond symptom management. Ongoing research and advancements in this field continue to expand the potential of regenerative therapies for musculoskeletal disorders, offering hope for improved outcomes and enhanced quality of life for patients. These factors contribute to the growth of the musculoskeletal disorders segment.
Regenerative Medicine Market by Region
Geographically, the global regenerative medicine market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America dominated the global regenerative medicine market with the largest revenue share of more than 45% in 2022, attributed to the availability of government and private funding, fast adoption of technology, and the presence of key market players. Additionally, companies across the region are continuously involved in launching new and advanced therapies, which are also expected to improve the regenerative medicine market outlook. For instance, in August 2022, Alexis Bio, a privately held regenerative medicine company, announced that their product, realSKIN, has become the first live cell xenotransplant product to receive Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA). The company's investigational therapy was undergoing Phase 3 clinical trials to assess its safety, tolerability, and efficacy. The trial aims to determine whether realSKIN can provide complete, long-lasting wound closure with a single application. The therapy aims to promote autologous skin regeneration in severe and extensive thermal burn wounds that require hospitalization, surgical excision, and skin grafting, where autografting is deemed clinically necessary.
Regenerative Medicine Market Competitive Landscape
The prominent players operating in the global regenerative medicine market are:
Regenerative Medicine Market Strategic Developments
Regenerative medicine is an interdisciplinary field that develops innovative approaches to repair, replace, or regenerate damaged or diseased cells, tissues, or organs.
The global regenerative medicine market was valued at US$ 11.9 billion in 2022.
The estimated market size of the global regenerative medicine market in 2031 is US$ 85.52 billion.
The revenue CAGR of the regenerative medicine market during the forecast period will be 24.5% from 2023 to 2031.
Some key players operating in the global regenerative medicine market are Tegoscience, Rocket Pharmaceuticals, Inc., Anterogen Co., Ltd., MIMEDX Group, Inc., CORESTEM Inc., Shenzhen SiBiono Genetech Co., Ltd., and Organogenesis Inc.
*Insights on financial performance are subject to the availability of information in the public domain